Fig. 3.

Comparison of progression-free survival of patients with newly diagnosed glioblastoma according to the HDRA sensitivity (n=12). A cut-off value of equal or more than 2 sensitive drugs (A) shows a tendency of prolonged progression-free survival in sensitive group (p=0.067), while that of total inhibition rate of more than 80% (B) fails to show statistical significance (p=0.17). Dotted line represents patients with HDRA sensitive result and solid line is for non-sensitive patients at each cut-off value. HDRA : Histoculture Drug Response Assay.